HomeAI · summaries
Storia in 3 fonti
China AI drug-design deals swell as US scrutiny mounts
Global pharmaceutical firms are tapping into Chinese artificial intelligence assets before patents expire on blockbuster drugs, advancing AI-driven biotech.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
asia.nikkei.com
Takeda and Insilico strike AI-led drug discovery deal worth up to $600m
Collaboration underlines surge in cross-border biotech licensing agreements
- ·
scmp.com
China AI drug-design deals swell as US scrutiny mounts
Global pharmaceutical firms are tapping into Chinese artificial intelligence assets before patents expire on blockbuster drugs, advancing AI-driven biotech.
